Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aldeyra Therapeutics Inc
ALDX | US
4.23
USD0.10
2.55%
ALDX | US
Loading StockChartView...
About Aldeyra Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/03/2026
Close
4.23
Open
4.38
High
4.45
Low
4.07
Aldeyra Therapeutics Inc. a biotechnology company develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap a reactive aldehyde species (RASP)modulator which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629 an orally administered RASP modulator for treatment of COVID-19 atopic asthma psoriasis and alcohol intoxication; and ADX-2191 a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer proliferative vitreoretinopathy and retinitis pigmentosa as well as rare retinal diseases characterized by inflammation and vision loss. In addition it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics Inc. and changed its name to Aldeyra Therapeutics Inc. in March 2014. Aldeyra Therapeutics Inc. was incorporated in 2004 and is based in Lexington Massachusetts.
View LessALDX | US
Risk
85.8
Sharpe
-0.38
Luna's Score
48/100
Recommendation
Hold
Luna says (ALDX | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
107.1%1 month
85.8%3 months
102.5%6 months
81.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.35
Debt to equity
0.16
Debt to assets
0.12
Ent. to EBITDA
-3.50
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-42.80M
MarketCap
251.35M
MarketCap(USD)
251.35M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-33.19
Short ratio
5.57
Short perc.
6.08
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.73
Range1M
1.73
Range3M
1.99
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
2.70
Price X volume
15.59M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.50 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.35 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 102.49 | 72.80 | Riskier |
| Debt to Equity | 0.16 | -1.23 | Expensive |
| Debt to Assets | 0.12 | 0.25 | Cheaper |
| Market Cap | 251.35M | 3.66B | Emerging |
